- Current report filing (8-K)
20 Abril 2012 - 11:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 20, 2012 (April 20, 2012)
ALLOS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado 80020
(Address of Principal Executive Offices)
(Zip Code)
Registrants telephone number, including area code: (303) 426-6262
N/A
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On April 20, 2012, Allos Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing that the European Medicines Agencys Committee For Medicinal
Products for Human Use confirmed its previous negative opinion issued in January 2012 on the Companys marketing authorisation application for FOLOTYN
®
(pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma whose disease has progressed after at least one prior systemic therapy. The
press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
|
|
|
99.1
|
|
Press Release, dated April 20, 2012, entitled Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN
®
in Europe.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated as of April 20, 2012
|
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Marc H. Graboyes
|
Name:
|
|
Marc H. Graboyes
|
Title:
|
|
Senior Vice President, General Counsel
|
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated April 20, 2012, entitled Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN
®
in Europe.
|
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024